Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CKD-846 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
CKD-846: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
C11-PHNO Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
C11-PHNO: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
AZD-4916 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
AZD-4916: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Brimarafenib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Brimarafenib: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
AZD0543 (AstraZeneca PLC) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
AZD0543 (AstraZeneca PLC): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risk
9 min read
DA-1726 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
DA-1726: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
YB1-X7 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
YB1-X7: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
IVL-3004 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
IVL-3004: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
MET-002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
MET-002: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
HIV vaccine(NuGenerex Immuno-Oncology, Inc.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
HIV vaccine(NuGenerex Immuno-Oncology, Inc.): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market pos
9 min read
3SC-009 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
3SC-009: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ROR1-TILs(Guangdong Zhaotai InVivo Biomedicine) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
ROR1-TILs(Guangdong Zhaotai InVivo Biomedicine): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market